Carcinoma of the prostate

New England Journal of Medicine

Volumn 324, Issue 4, 1991, Pages 236-245

  Gittes, Ruben F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW;

EID: 0025974356     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199101243240406     Document Type: Review

References (150)

1. Klein L.A. Prostatic carcinoma. N Engl J Med 1979; 300:824-833
2. Silverberg E., Lubera J.A. Cancer statistics, 1989. CA 1989; 39:3-20.
3. Noble R.L. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 1977; 37:1927-1933
4. Murphy G.P., ed. Models for prostate cancer. Vol. 37 of Progress in clinical and biological research. New York: Alan R. Liss, 1980.
5. Viola M.V., Fromowitz F., Oravez S., et al. Expression of ras oncogene p21 in prostate cancer. N Engl J Med 1986; 314:133-137
6. Thompson T.C., Southgate J., Kitchener G., Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 1989; 56:917-930
7. Zaridze D.G., Boyle P. Cancer of the prostate: epidemiology and etiology. Br J Urol 1987; 59:493-502.
8. Ross R.K., Paganini-Hill A., Henderson B.E. Epidemiology of prostatic cancer. In: Skinner DG, Lieskovsky G, eds. Diagnosis and management of genitourinary cancer. Philadelphia: W.B. Saunders, 1988: 40-5.
9. Scott R. Jr., Mutchnik D.L., Laskowski T.Z., Schmalhorst W.R. Carcinoma of the prostate in elderly men: incidence, growth characteristics and clinical significance. J Urol 1969; 101:602-607
10. Sheldon C.A., Williams R.D., Fraley E.E. Incidental carcinoma of the prostate: a review of the literature and critical reappraisal of classification. J Urol 1980; 124:626-631
11. Levine R.L., Wilchinsky M. Adenocarcinoma of the prostate: a comparison of the disease in blacks versus whites. J Urol 1979; 121:761-762
12. Dayal H.H., Prolissar L., Dahlberg S. Race, socioeconomic status, and other prognostic factors for survival from prostate cancer. J Natl Cancer Inst 1985; 74:1001-1006
13. Yatani R., Chigusa K., Akazaki K., Stemmerman G.N., Welsh R.A., Correa P. Geographic pathology of latent prostatic carcinoma. Int J Cancer 1982; 29:611-616
14. Guileyardo J.M., Johnson W.D., Welsh R.A., Akazaki K., Correa P. Prevalence of latent prostate carcinoma in two U.S. populations. J Natl Cancer Inst 1980; 65:311-316
15. Ross R.K., Bernstein L., Judd H., Hanisch R., Pike M., Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 1986; 76:45-48
16. Hill P.B., Wynder E.L. Effect of a vegetarian diet on dexamethasone on plasma prolactin, testosterone and dehydroepiandrosterone in men and women. Cancer Lett 1979; 7:273-282
17. Steinberg G.D., Carter B.S., Beaty T.L., Childs B., Walsh P.C. The familial aggregation of prostate cancer: a case control study. J Urol 1990; 143:313A. abstract.
18. Kabalin J.N., McNeal J.E., Price H.M., Freiha F.S., Stamey T.A. Unsuspected adenocarcinoma of the prostate in patients undergoing cytoprostatectomy for other causes: incidence, histology and morphometric observations. JUrol 1989; 141:1091-1094
19. McNeal J.E., Bostwick D.G., Kindrachuk R.A., Redwine E.A., Freiha F.S., Stamey T.A. Patterns of progression in prostate cancer. Lancet 1986; 1:60-63
20. McNeal J.E., Redwine E.A., Freiha F.S., Stamey T.A. Zonal distribution of prostatic adenocarcinoma: correlation with histologie pattern and direction of spread. Am J Surg Pathol 1988; 12:897-906.
21. Byar D.P., Mostofi F.K. Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies: examined by the step-section technique. Cancer 1972; 30:5-13.
22. Stamey T.A., McNeal J.E., Freiha F.S., Redwine E. Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol 1988; 139:1235-1241
23. Villers A., McNeal J.E., Redwine E., Freiha F.S., Stamey T.A. The role of perineural space invasion in the local spread of prostate adenocarcinoma. J Urol 1989; 142:763-768
24. Fowler J.E. Jr., Whitmore W.F. Jr. The incidence and extent of pelvic lymph node metastases in apparently localized prostate cancer. Cancer 1981; 47:2941-2945
25. Saitoh H., Hida M., Shimbo T., Nakamura K., Yamagata J., Satoh T. Metastatic patterns of prostate cancer: correlation between sites and number of organs involved. Cancer 1984; 54:3078-3084
26. Chodak G.W., Keller P., Schoenberg H.W. Assessment of screening for prostate cancer using digital rectal examination. J Urol 1989; 141:1136-1138
27. Lee F., Torp-Pedersen S., Littrup P.J., et al. Hypoechoic lesions of the prostate: clinical relevance of tumor size, digital rectal examination, and prostate-specific antigen. Radiology 1989; 170:29-32.
28. Hodge K., McNeal J.E., Terris M.K., Stamey T.A. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 141:71-74
29. Hodge K.K., McNeal J.E., Stamey T.A. Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J Urol 1989; 142:66-70.
30. Scardino P.T. Early detection of prostate cancer. Urol Clin North Am 1989; 16:635-655
31. Chodak G.W., Bibbo M., Straus F.H. II, Wied G.L. Transrectal aspiration versus transperineal core biopsy for the diagnosis of carcinoma of the prostate. J Urol 1984; 123:480-482
32. Benson M.C. Fine-needle aspiration of the prostate. In: NCI monographs. No. 7. Washington, D.C.: Government Printing Office, 1988: 19-24. (NIH publication no. 88–3005.)
33. Ragde H., Aldape H.C., Bagley C.M. Jr. Ultrasound-guided prostate biopsy: Biopty gun superior to aspiration. Urology 1988; 32:503-506
34. Kaye K.W., Horwitz C.A. Transrectal ultrasound-guided prostate biopsies using new automatic gun: analysis of 100 consecutive cases. J Endourol 1989; 3:155-162
35. Lee F., Littrup P.J., Torp-Pedersen S.T., et al. Prostate cancer: comparison of transrectal US and digital rectal examination for screening. Radiology 1988; 168:389-394
36. Nesbitt J.A., Drago J.R., Badalament R.A. Transrectal ultrasonography: early experience with use as prostate cancer detection tool. Urology 1989; 34:120-122
37. Cooner W.H., Mosley B.R., Rutherford C.L. Jr., et al. Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostate cancer. J Urol 1988; 139:758-761
38. Ragde H., Bagley C.M. Jr., Aldape H.C., Blasko J.C. Screening for prostatic cancer with high-resolution ultrasound. J Endourol 1989; 3:115-124
39. Muldoon L., Resnick M.I. Results of ultrasonography of the prostate. Urol Clin North Am 1989; 16:693-702.
40. Perrin P., Mouriquand P., Monsallier M., Oukheira H., Maquet J.H., Devonec M. Hypothetical place of transrectal ultrasound in the diagnosis of prostatic cancer at an early stage. J Endourol 1989; 3:109-114
41. Chodak G.W. Screening for prostate cancer: role of ultrasonography. Urol Clin North Am 1989; 16:657-661
42. Stamey T.A. Prostate cancer: some basic clinical and morphometric observations. Urology Monogr 1989; 10:79-91.
43. Wang M.C., Valenzuela L.A., Murphy G.P., Chu T.M. Purification of a human prostate specific antigen. Invest Urol 1979; 17:159-163
44. Ford T.F., Butcher D.N., Masters J.R., Parkinson M.C. Immunocytochemical localisation of prostate-specific antigen: specificity and application to clinical practice. Br J Urol 1985; 57:50-55
45. Hortin G.L., Bahnson R.R., Daft M., Chan K.-M., Catalona W.J., Ladenson J.H. Differences in values obtained with 2 assays of prostate specific antigen. J Urol 1988; 139:762-765
46. Chan D.W., Bruzek D.J., Oesterling J.E., Rock R.C., Walsh P.C. Prostate-specific antigen as a marker for prostatic cancer: a monoclonal and a polyclonal immunoassay compared. Clin Chem 1987; 33:1916-1920
47. Stamey T.A., Yang N., Hay A.R., McNeal J.E., Freiha F.S., Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317:909-916
48. Gittes R.F. Prostate-specific antigen. N Engl J Med 1987; 317:954-955
49. Stamey T.A. Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. Urology Monogr 1989; 10:50-64.
50. Lange P.H., Brawer M.K. Serum prostate-specific antigen: its use in diagnosis and management of prostate cancer. Urology 1989; 33:Suppl 6:13-17
51. Hudson M.A., Bahnson R.R., Catalona W.J. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 1989; 142:1011-1017
52. Brawer M.K., Schifman R.B., Ahmann F.R., Ahmann M.E., Coulis K.M. The effect of digital rectal examination on serum levels of prostate-specific antigen. Arch Pathol Lab Med 1988; 112:1110-1112
53. Dalton D.L. Elevated serum prostate-specific antigen due to acute bacterial prostatitis. Urology 1989; 33:465.
54. Stamey T.A., Kabalin J.N. Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. J Urol 1989; 141:1070-1075
55. Schnall M.D., Lenkinski R.E., Pollack H.M., Imai Y., Kressel H.Y. Prostate: MR imaging with an endorectal surface coil. Radiology 1989; 172:570-574
56. Mostofi F.K. Grading of prostatic carcinoma. Cancer Chemother Rep 1975; 59:111-117
57. Epstein J.I., Berry S.J., Eggleston J.C. Nuclear roundness factor: a predictor of progression in untreated Stage A2 prostate cancer. Cancer 1984; 54:1666-1671
58. Gleason D.F. The Veterans Administration Cooperative Urologic Research Group: histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, ed. Urologic pathology: the prostate. Philadelphia: Lea & Febiger, 1977: 171-98.
59. Gaeta J.F., Englander L.C., Murphy G.P. Comparative evaluation of National Prostatic Cancer Treatment Group and Gleason systems for pathologic grading of primary prostatic cancer. Urology 1986; 27:306-308
60. Paulson D., Piserchia P.V., Gardner W. Predictors of lymphatic spread in prostatic adenocarcinoma: uro-oncology research group study. J Urol 1980; 123:697-699
61. Oesterling J.E., Brendler C.B., Epstein J.I., Kimball A.W. Jr., Walsh P.C. Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathologic stage in 275 patients with clinically localized adenocarcinoma of the prostate. J Urol 1987; 138:92-98
62. Allhoff E.P., Proppe K.H., Chapman C.M., Lin C.-H., Prout G.R. Jr. Evaluation of prostate specific acid phosphatase and prostate specific antigen in identification of prostatic cancer. J Urol 1983; 129:315-318
63. Hricak H. Noninvasive imaging for staging of prostate cancer: magnetic resonance imaging, computed tomography, and ultrasound. In: NCI monographs. No. 7. Washington, D.C.: Government Printing Office, 1988: 31-5. (NIH publication no. 88–3005.)
64. Scardino P.T., Shinohara K., Wheeler T.M., Carter S.S. Staging of prostate cancer: value of ultrasonography. Urol Clin North Am 1989; 16:713-734
65. Middleton R.G. Value of and indications for pelvic lymph node dissection in the staging of prostate cancer. In: NCI monographs. No. 7. Washington, D.C.: Government Printing Office, 1988: 41-3. (NIH publication no. 88–3005.)
66. Gervasi L.A., Mata J., Easley J.D., et al. Prognostic significance of lymph nodal metastases in prostatic cancer. J Urol 1989; 142:332-336
67. Smith J.A. Jr., Cho Y.-H. Management of stage A prostate cancer. Urol Clin North Am 1990; 17:769-777
68. Lange P.H. Controversies in management of apparently localized cancer of the prostate. Urology 1989; 34:Suppl 4:13-18
69. Paulson D.F. Randomized series of treatment with surgery versus radiation for prostate adenocarcinoma. In: NCI monographs. No. 7. Washington, D.C.: Government Printing Office, 1988: 127-31. (NIH publication no. 88–3005.)
70. Bagshaw M.A., Cox R.S., Ray G.R. Status of radiation treatment of prostate cancer at Stanford University. In: NCI monographs. No. 7. Washington, D.C.: Government Printing Office, 1988: 47-60. (NIH publication no. 88–3005.)
71. Blute M.L., Nativ O., Zincke H., Farrow G.M., Therneau T., Lieber M.M. Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy. J Urol 1989; 142:1262-1265
72. Gibbons R.P. Total prostatectomy for clinically localized prostate cancer: long-term surgical results and current morbidity. In: NCI monographs. No. 7. Washington, D.C.: Government Printing Office, 1988: 123-6. (NIH publication no. 88–3005.)
73. Lepor H., Walsh P.C. Long-term results of radical prostatectomy in clinically localized prostate cancer: experience at The Johns Hopkins Hospital. In: NCI monographs. No. 7. Washington, D.C.: Government Printing Office, 1988: 117-22. (NIH publication no. 88–3005.)
74. Walsh P.C., Donker P.J. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 1982; 128:492-497
75. Walsh P.C. Radical retropubic prostatectomy with reduced morbidity: an anatomic approach. In: NCI monographs. No. 7. Washington, D.C.: Government Printing Office, 1988: 133-7. (NIH publication no. 88–3005.)
76. Walsh P.C., Epstein J.I., Lowe F.C. Potency following radical prostatectomy with wide unilateral excision of the neurovascular bundle. J Urol 1987; 138:823-827
77. Reiner W.G., Walsh P.C. An anatomical approach to the surgical management of the dorsal vein and Santorini#x0027;s plexus during radical retropubic surgery. J Urol 1979; 121:198-200.
78. Peters C.A., Walsh P.C. Blood transfusion and anesthetic practices in radical retropubic prostatectomy. J Urol 1985; 134:81-83
79. Zincke H. Extended experience with surgical treatment of Stage D1 adenocarcinoma of the prostate: significant improvement of immediate adjuvant hormonal treatment (orchiectomy) on outcome. Urology 1989; 33:Suppl 5:27-36.
80. Bigg S.W., Catalona W.J. Advisability of performing nerve-sparing radical prostatectomy for stage B2 prostate cancer. J Urol 1989; 141:345A.
81. Stamey T.A., Freiha F.S. The Stanford radical retropubic prostatectomy (RRP). J Urol 1990; 143:315A. abstract.
82. O#x0027;Donnell P., Finan B.F. Continence following nerve-sparing radical prostatectomy. J Urol 1989; 142:1227-1229
83. Basinger G.T., Gittes R.F. Lymphocyst: ultrasound diagnosis and urologic management. J Urol 1975; 114:740-745
84. Sogani P.C., Watson R.C., Whitmore W.F. Jr. Lymphocele after pelvic lymphadenectomy for urologic cancer. Urology 1981; 17:39-43.
85. Krane R.J., Goldstein I., de Tejada I.S. Impotence. N Engl J Med 1989; 321: 1648-59.
86. Stamey T.A., Kabalin J.N., McNeal J.E., et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989; 141:1076-1083
87. Whitmore W.F. Jr., Hilaris B.S., Grabstald H. Retropubic implantation to I125 in the treatment of prostate cancer. J Urol 1972; 108:918-920
88. Carlton C.E. Jr., Hudgins P.T., Guerriero W.G., et al. Radiotherapy in the management of stage C carcinoma of the prostate. J Urol 1976; 116:206-210
89. Schellhammer P.F., el-Mahdi A.M., Higgins E.M., Schultheiss T.E., Ladaga L.E., Babb T.J. Prostate biopsy after definitive treatment by interstitial 125iodine implant or external beam radiation therapy. J Urol 1987; 137:897-901.
90. Scardino P.T., Wheeler T.M. Local control of prostate cancer with radiotherapy: frequency and prognostic significance of positive results of postirradiation prostate biopsy. In: NCI monographs. No. 7. Washington, D.C.: Government Printing Office, 1988: 95-103. (NIH publication no. 88–3005.)
91. Fair W.R., Herr H.W., Morse M.J., Russo P., Sogani P.C., Whitmore W.F. Jr. Early experience with 100 radical retropubic prostatectomies and interstitial 125iodine: the MSKCC experience. J Urol 1989; 142:282A. abstract.
92. Snyder P., Lytton B. I125 seen implant for prostate cancer: a 10 year follow-up. J Urol 1989; 142:309A. abstract.
93. Holm H.H., Juul N., Pederson J.F., Hansen H., Stryer I. Transperineal I125 seed implantation in prostate cancer guided by transrectal ultrasonography. J Urol 1983; 130:283-286
94. Loening S.A., Ekon E.D. Percutaneous transperineal placement of radioactive gold seeds for treatment of localized prostatic carcinoma. J Endourol 1989; 3:201-209
95. Carter S.S., Torp-Pedersen S.T., Holm H.H. Ultrasound-guided implantation techniques in the treatment of prostate cancer. Urol Clin North Am 1989; 16:751-762
96. Bagshaw M.A., Kaplan H.S., Sagerman R.H. Linear accelerator supervoltage radiotherapy. VII: carcinoma of the prostate. Radiology 1965; 85:121-129
97. Shipley W.U., Prout G.R. Jr., Coachman N.M., et al. Radiation therapy for localized prostate carcinoma: experience at the Massachusetts General Hospital (1973–1981). In: NCI monographs. No. 7. Washington, D.C.: Government Printing Office, 1988: 67-73. (NIH publication no. 88–3005.)
98. Laramore G.E., Krall J.M., Thomas F.J., Griffin T.W., Maor M.H., Hendrickson F.R. Fast neutron radiotherapy for locally advanced prostate cancer: results of an RTOG randomized study. Int J Radiat Oncol Biol Phys 1985; 11:1621-1627
99. Pilepich M.V. Radiation Therapy Oncology Group studies in carcinoma of the prostate. In: NCI monographs. Washington, D.C.: Government Printing Office, 1988: 61-5. (NIH publication no. 88–3005.)
100. Asbell S.O., Krall J.M., Pilepich M.V., et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77–06. Int J Radiat Oncol Biol Phys 1988; 15:1307-1316
101. Hanks G.E. External-beam radiation therapy for clinically localized prostate cancer: Patterns of Care Studies in the United States. In: NCI monographs. No. 7. Washington, D.C.: Government Printing Office, 1988: 75-84. (NIH publication no. 88–3005.)
102. Goldstein I., Feldman M.I., Deckers P.J., Babayan R.K., Krane R.J. Radiation-associated impotence: a clinical study of its mechanism. JAMA 1984; 251:903-910
103. Stamey T.A., Kabalin J.N., Ferrari M. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients. J Urol 1989; 141:1084-1087
104. Kabalin J.N., Hodge K.K., McNeal J.E., Freiha F.S., Stamey T.A. Identification of residual cancer in the prostate following radiation therapy: role of transrectal ultrasound guided biopsy and prostate specific antigen. J Urol 1989; 142:326-331
105. Egawa S., Carter S.S., Wheeler T.M., Scardino P.T. Ultrasonographic changes in the normal and malignant prostate after definitive radiotherapy. Urol Clin North Am 1989; 16:741-749
106. Nachtsheim D.A. Jr., McAnnich J.W., Stutzman R.E., Goebel J.L. Latent residual tumor following external radiotherapy for prostate adenocarcinoma. J Urol 1978; 120:312-314
107. Herr H.W., Whitmore W.F. Jr. Significance of prostatic biopsies after radiation therapy for carcinoma of the prostate. Prostate 1982; 3:339-350
108. Freiha F.S., Bagshaw M.A. Carcinoma of the prostate: results of post-irradiation biopsy. Prostate 1984; 5:19-25.
109. Scardino P.T., Frankel J.F., Wheeler T.M., et al. The prognostic significance of post-irradiation biopsy results in patients with prostatic cancer. J Urol 1986; 135:510-516
110. Kiesling V.J., McAninch J.W., Goebel J.L., Agee R.E. External beam radio-therapy for adenocarcinoma of the prostate: a clinical follow up. J Urol 1980; 124:851-854
111. Leach G.E., Cooper J.F., Kagan A.R., Snyder R., Forsythe A. Radiotherapy for prostatic carcinoma: post-irradiation prostatic biopsy and recurrence patterns with long-term follow up. J Urol 1982; 128:505-509
112. Neerhut G.J., Wheeler T., Cantini M., Scardino P.T. Salvage radical prostatectomy for radiorecurrent adenocarcinoma of the prostate. J Urol 1988; 140:544-549
113. Hanks G.E. Treatment of locally advanced prostate cancer with radiation therapy. Urology 1989; 33:Suppl 5:37-41.
114. Byar D.P., Corle D.K. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. In: NCI monographs. No. 7. Washington, DC: Government Printing Office, 1988: 165-70. (NIH publication no. 88–3005.)
115. McCullough D.G., Leadbetter W.F. Radical pelvic surgery for locally extensive carcinoma of the prostate. J Urol 1972; 108:939-943
116. Schroeder F.H., Belt E. Carcinoma of the prostate: a study of 213 patients with stage C tumors treated by total perineal prostatectomy. J Urol 1975; 114:257-260
117. Zincke H., Utz D.C., Taylor W.F. Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C prostatic cancer: role of adjuvant treatment for residual cancer and in disease progression. J Urol 1986; 135:1199-1205
118. Paulson D.F., Cline W.A. Jr., Koefoot R.B. Jr., Hinshaw W., Stephani S. Extended field radiation therapy versus delayed hormonal therapy in node positive prostatic adenocarcinoma. J Urol 1982; 127:935-937
119. Fallon B., Williams R.D. Current options in the management of clinical stage C prostatic carcinoma. Urol Clin North Am 1990; 17:853-866
120. Huggins C., Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1:293-297
121. Walsh P.C. Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am 1975; 2:125-140
122. Glenn J.F. Subepididymal orchiectomy: an acceptable alternative. J Urol 1990; 144:942-944
123. de Voogt H.J., Smith P.H., Pavone-Macaluso M., de Pauw M., Suciu S. Cardiovascular side effects of diethylstilbestrol, cryproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 1986; 135:303-307
124. Shearer R.J., Hendry W.F., Sommerville I.F., Fergusson J.D. Plasma testosterone: an accurate monitor of hormonal treatment in prostatic cancer. Br J Urol 1973; 45:668-677
125. Gagnon J.D., Moss W.T., Stevens K.R. Pre-estrogen breast irradiation for patients with carcinoma of the prostate: a critical review. J Urol 1979; 121:182-184
126. The Veterans Administration Cooperative Urological Research Group. Carcinoma of the prostate: treatment comparisons. J Urol 1967; 98:516-522
127. Stamey T.A., Kabalin J.N., Ferrari M., Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Antiandrogen treated patients. J Urol 1989; 141:1088-1090
128. Schally A.V., Arimura A., Baba Y., et al. Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun 1971; 43:393-399
129. Schally A.V., Redding T.W., Comaru-Schally A.M. Inhibition of prostate tumors by agonistic and antagonistic analogs of LH-RH. Prostate 1983; 4:545-552
130. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984; 311:1281-1286
131. The Leuprolide Study Group. Clinical study of depot leuprolide in the treatment of advanced prostate cancer. J Urol 1989; 141:346A. abstract.
132. Blackledge G., Emtage L.A., Trethowan C., et al. “Zoladex” depot vs DES 3 mg/day in advanced prostate cancer: a randomised trial comparing efficacy and tolerability. J Urol 1989; 141:347a. abstract.
133. Kuhn J.-M., Billebaud T., Navratil H., et al. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med 1989; 321:413-418
134. Stein B.S., Smith J.A. Jr. DES lead-in to use of luteinizing hormone releasing hormone analogs in treatment of metastatic carcinoma of prostate. Urology 1985; 25:350-353
135. Huggins C.E., Scott W.W. Bilateral adrenalectomy in prostatic cancer: clinical features and urinary excretion of 17-ketosteroids and estrogen. Ann Surg 1945; 122:1031-1041
136. Scott W.W., Menon M., Walsh P.C. Hormonal therapy of prostatic cancer. Cancer 1980; 45:Suppl 7:1929-1936
137. Walsh P.C., Gittes R.F. Inhibition of extratesticular stimuli to prostatic growth in the castrate rat by antiandrogens. Endocrinology 1970; 87:624-627
138. Pavone-Macaluso M., Pavone C., Serretta V., Daricello G. Antiandrogens alone or in combination for treatment of prostate cancer: the European experience. Urology 1989; 34:Suppl 4:27-36.
139. McConnell J.D. Androgen ablation and blockade in the treatment of benign prostatic hyperplasia. Urol Clin North Am 1990; 17:661-670
140. Labrie F., Dupont A., Belanger A., et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 1982; 5:267-275
141. Labrie. New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and antiandrogen. J Steroid Biochem 1983; 19:999-1007.
142. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321:419-424
143. Iversen P., Wolf H., Hvidt V., Karup T., Rassmussen F., Danish Prostate Cancer Group. Zoladex plus flutamide vs. orchiectomy in the treatment of advanced prostatic cancer. J Urol 1989; 141:348A.
144. Trachtenberg J., Beland G., Elhilali M.M., et al. A randomized trial of total androgen ablation vrs orchiectomy in patients with metastatic prostatic cancer. J Urol 1989; 141:347A.
145. Fourcade R.O., Cariou G., Coloby P., et al. Total androgen blockade in advanced prostatic carcinoma: interim report of a double blind study using Zoladex and Flutamide. J Urol 1990; 143:220A.
146. Di Silverio F., Serio M., Costantini A. The use of the LHRH analogue goserelin alone or in combination with the antiandrogen cyproterone acetate in the treatment of advanced prostatic carcinoma: an Italian multicentric trial. J Urol 1990; 143:308A.
147. Holdaway I., Altwein J.E., Kiippel K.F., Lunglmayr G., Tyrrell C.J., Varenhorst E. A multicentre randomised trial comparing the LHRH agonist “Zoladex” with “Zoladex” in combination with Flutamide in the treatment of advanced prostate cancer. J Urol 1990; 143:220A.
148. Eisenberger M.A. Chemotherapy for prostate carcinoma. In: NCI monographs. No. 7. Washington, D.C.: Government Printing Office, 1988: 151-63. (NIH publication no. 88–3005.)
149. Manni A., Santen R.J., Boucher A.E., et al. Androgen priming and response to chemotherapy in advanced prostatic cancer. J Urol 1986; 136:1242-1246
150. Fowler J.E. Jr., Whitmore W.F. Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981; 126:372-375